How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Sell
41
UCBJY Quote, Financials, Valuation and Earnings
Last price:
$88.29
Seasonality move
:
7.56%
Day range:
$89.01 - $89.65
52-week range:
$60.76 - $106.60
Dividend yield:
0.81%
P/E ratio:
30.49x
P/S ratio:
5.27x
P/B ratio:
3.25x
Volume:
23.7K
Avg. volume:
47.7K
1-year change:
44.8%
Market cap:
$33.9B
Revenue:
$6.7B
EPS (TTM):
$2.93
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, UCB SA has -- downside to fair value with a price target of -- per share.
UCBJY vs. S&P 500
-
Over the past 5 trading days, UCB SA has underperformed the S&P 500 by -6.52% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
UCB SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
UCB SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter UCB SA reported revenues of --.
Earnings Growth
-
UCB SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter UCB SA reported earnings per share of --.
Enterprise value:
35B
EV / Invested capital:
--
Price / LTM sales:
5.27x
EV / EBIT:
24.79x
EV / Revenue:
5.32x
PEG ratio (5yr expected):
0.19x
EV / Free cash flow:
35.62x
Price / Operating cash flow:
35.32x
Enterprise value / EBITDA:
16.68x
Gross Profit (TTM):
$4.7B
Return On Assets:
6.57%
Net Income Margin (TTM):
17.27%
Return On Equity:
11.39%
Return On Invested Capital:
8.72%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-04-01 | 2024-04-01 | 2024-04-01 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $4.4B | $4.2B | $3.5B | $3.8B | $5B | |
| Total Assets | $16.4B | $16.1B | $17B | $17.2B | $18.1B | |
| Current Liabilities | $3.5B | $3.2B | $3.3B | $2.9B | $3.7B | |
| Total Liabilities | $7.4B | $6.6B | $7.3B | $7.3B | $7.6B | |
| Total Equity | $8.9B | $9.5B | $9.7B | $9.9B | $10.4B | |
| Total Debt | $3.2B | $2.3B | $3B | $3.2B | $2.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-04-01 | 2024-04-01 | 2024-04-01 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
UCBJY
Sector
Market Cap
$33.9B
$36.4M
Price % of 52-Week High
83.7%
44.07%
Dividend Yield
0.81%
0%
Shareholder Yield
1.24%
-1.03%
1-Year Price Total Return
44.8%
-41.85%
Beta (5-Year)
0.781
0.775
Dividend yield:
0.81%
Annualized payout:
$0.72
Payout ratio:
24.52%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$94.15
200-day SMA
Sell
Level
$90.80
Bollinger Bands (100)
Sell
Level
93.62 - 100.2
Chaikin Money Flow
Buy
Level
2.4M
20-day SMA
Sell
Level
$97.87
Relative Strength Index (RSI14)
Sell
Level
36.04
ADX Line
Sell
Level
13.73
Williams %R
Buy
Level
-98.2914
50-day SMA
Sell
Level
$97.25
MACD (12, 26)
Sell
Level
-1.79
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
2.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.2747)
Buy
CA Score
(Annual)
Level (0.4066)
Buy
Beneish M-Score
(Annual)
Level (-2.3834)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-2.0086)
Buy
Piotroski F Score
(Annual)
Level (9)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).
Stock Forecast FAQ
In the current month, UCBJY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The UCBJY average analyst price target in the past 3 months is --.
-
Where Will UCB SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that UCB SA share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About UCB SA?
Analysts are divided on their view about UCB SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that UCB SA is a Sell and believe this share price will rise from its current level to --.
-
What Is UCB SA's Price Target?
The price target for UCB SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is UCBJY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for UCB SA is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of UCBJY?
You can purchase shares of UCB SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase UCB SA shares.
-
What Is The UCB SA Share Price Today?
UCB SA was last trading at $88.29 per share. This represents the most recent stock quote for UCB SA. Yesterday, UCB SA closed at $89.22 per share.
-
How To Buy UCB SA Stock Online?
In order to purchase UCB SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Is JHX Stock a Buy Sell or Hold?
James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 31
Ajinomoto [AJINY] is down 2.15% over the past day.
Sell
40
RGC alert for Mar 31
Regencell Bioscience Holdings [RGC] is up 26.1% over the past day.
Buy
69
AGX alert for Mar 31
Argan [AGX] is down 4.98% over the past day.
